ALX Oncology Holdings Inc (ALXO)
1.34
+0.05
(+3.88%)
USD |
NASDAQ |
Nov 22, 10:38
ALX Oncology Holdings Shareholders Equity (Quarterly): 136.81M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 136.81M |
| June 30, 2024 | 159.32M |
| March 31, 2024 | 164.20M |
| December 31, 2023 | 189.71M |
| September 30, 2023 | 168.75M |
| June 30, 2023 | 212.69M |
| March 31, 2023 | 240.39M |
| December 31, 2022 | 263.46M |
| September 30, 2022 | 286.96M |
| June 30, 2022 | 316.32M |
| Date | Value |
|---|---|
| March 31, 2022 | 343.60M |
| December 31, 2021 | 363.05M |
| September 30, 2021 | 385.17M |
| June 30, 2021 | 405.01M |
| March 31, 2021 | 418.48M |
| December 31, 2020 | 429.84M |
| September 30, 2020 | 252.02M |
| June 30, 2020 | 90.64M |
| March 31, 2020 | 99.12M |
| December 31, 2019 | -0.276M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-0.276M
Minimum
Dec 2019
429.84M
Maximum
Dec 2020
246.26M
Average
246.20M
Median
Shareholders Equity (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 5.413B |
| Neurocrine Biosciences Inc | 2.719B |
| Eton Pharmaceuticals Inc | 15.98M |
| Verve Therapeutics Inc | 508.55M |
| Immuneering Corp | 57.72M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 185.72M |
| Total Liabilities (Quarterly) | 48.91M |